Corline Biomedical Second Quarter 2025 Earnings: kr0.13 loss per share (vs kr0.20 loss in 2Q 2024)

Corline Biomedical (STO:CLBIO) Second Quarter 2025 Results

Key Financial Results

• Revenue: kr2.63m (down 60% from 2Q 2024).
• Net loss: kr3.26m (loss narrowed by 26% from 2Q 2024).
• kr0.13 loss per share (improved from kr0.20 loss in 2Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Corline Biomedical Earnings Insights

Looking ahead, revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 29% growth forecast for the Pharmaceuticals industry in Sweden.

Performance of the Swedish Pharmaceuticals industry.

The company's shares are up 2.4% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 3 warning signs for Corline Biomedical (of which 1 doesn't sit too well with us!) you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.